Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Review Article and Clinical Experience METABOLIC SYNDROME VS INSULIN RESISTANCE SYNDROME (A CLUSTER OF COMPONENTS AND STRATEGIES FOR TREATMENT)

Folia Medica Indonesiana · Vol. 41 No. 1 (2005)

ISSN
2355-8393, 2599-056X
Terbit
2005-01-01
Penerbit
Airlangga University
Bahasa
en

Abstrak

Metabolic Syndrome = MS (in which abdominal Obesity is the culprit of the MS) is defined by NCEP-ATP III in 2001, whereas Dysmetabolic Syndrome = DMS and Insulin Resistance Syndrome = IRS are recommended terms by AACE (in 2002) and ACE (in 2002), respectively. Both AACE and ACE stated that insulin resistance plays central role in the syndrome. All these terms of the syndrome are originally and firstly coined by Reaven as Syndrome-X in 1988, and then Metabolic Syndrome-X in 1999. Either MS or DMS or IRS has become major issues because of its impact on the risks of Type 2 DM (T2DM) development and cardiovascular diseases. The criteria of MS, IRS (including its risk factors), and the clusters of components belong to MS and IRS, are listed in this paper. Rational strategies for the treatment of MS and IRS are focused on obesity and insulin resistance, respectively, and can be summarized as follows A. Improving insulin sensitivity and lifestyle (weight loss 5-10%, aerobic exercise ± 30-40 min, 4 times/week). B. Pharmacological Interventions directed to the targets for (mmHg, ml/dl) Blood Pressure 40 for men, and > 50 for women. Clinical evidence-based data supported, that Metformin (UKPDS Outcomes), Sibutramine (STORM Landmark Trial), and Orlistat (XENDOS Study), to date, are the promising drugs for the treatment of MS/IRS. However, the drugs specifically to improve the insulin sensitivity are hoped to treat this Syndrome. Conclusions Syndrome-X, Metabolic Syndrome-X, MS, DMS, or IRS, all have become major issues because of their roles in the development of either T2DM or Cardiovascular Diseases. The cluster of components of this Syndrome and its risk factors should be well recognized. Improving insulin sensitivity, losing body weight, aerobic exercise, and pharmacologic interventions (Metformin, Sibutramin, Orlistat) are rational strategies for the treatment of MS/IRS.

Kata kunci

Jaringan kolaborasi para penulis

8 penulis · 16 tautan kepenulisan bersama · 7 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAfiliasi tidak diketahui1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article and Clinical Experience METABOLIC SYNDROME VS INSULIN RESISTANCE SYNDROME (A CLUSTER OF COMPONENTS AND STRATEGIES FOR TREATMENT)</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>metabolic syndrome</dc:subject><dc:subject>dysmetabolic syndrome</dc:subject><dc:subject>abdominal obesity</dc:subject><dc:subject>insulin resistance</dc:subject><dc:subject>type 2 diabetes</dc:subject><dc:subject>cardiovascular risk</dc:subject><dc:subject>insulin sensitivity</dc:subject><dc:subject>weight loss</dc:subject><dc:subject>aerobic exercise</dc:subject><dc:subject>metformin</dc:subject><dc:subject>sibutramine</dc:subject><dc:subject>orlistat</dc:subject><dc:subject>NCEP ATP III criteria</dc:subject><dc:description xml:lang="en">Metabolic Syndrome = MS (in which abdominal Obesity is the culprit of the MS) is defined by NCEP-ATP III in 2001, whereas Dysmetabolic Syndrome = DMS and Insulin Resistance Syndrome = IRS are recommended terms by AACE (in 2002) and ACE (in 2002), respectively. Both AACE and ACE stated that insulin resistance plays central role in the syndrome. All these terms of the syndrome are originally and firstly coined by Reaven as Syndrome-X in 1988, and then Metabolic Syndrome-X in 1999. Either MS or DMS or IRS has become major issues because of its impact on the risks of Type 2 DM (T2DM) development and cardiovascular diseases. The criteria of MS, IRS (including its risk factors), and the clusters of components belong to MS and IRS, are listed in this paper. Rational strategies for the treatment of MS and IRS are focused on obesity and insulin resistance, respectively, and can be summarized as follows A. Improving insulin sensitivity and lifestyle (weight loss 5-10%, aerobic exercise ± 30-40 min, 4 times/week). B. Pharmacological Interventions directed to the targets for (mmHg, ml/dl) Blood Pressure 40 for men, and &gt; 50 for women. Clinical evidence-based data supported, that Metformin (UKPDS Outcomes), Sibutramine (STORM Landmark Trial), and Orlistat (XENDOS Study), to date, are the promising drugs for the treatment of MS/IRS. However, the drugs specifically to improve the insulin sensitivity are hoped to treat this Syndrome. Conclusions Syndrome-X, Metabolic Syndrome-X, MS, DMS, or IRS, all have become major issues because of their roles in the development of either T2DM or Cardiovascular Diseases. The cluster of components of this Syndrome and its risk factors should be well recognized. Improving insulin sensitivity, losing body weight, aerobic exercise, and pharmacologic interventions (Metformin, Sibutramin, Orlistat) are rational strategies for the treatment of MS/IRS.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2005-01-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>http://journal.unair.ac.id/filerPDF/Ask%200403.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 41 No 1 (2005)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>